Phyllis Ferrell MBA, MA

Phyllis Ferrell is the Vice President, and Global Alzheimer’s Disease Platform Team Leader in Lilly BioMedicines. Phyllis and her team are responsible for the late-stage development and global registration of Solanezumab, Amyvid and AZD3293, including global launches and commercialization. The team is also planning for several other earlier stage assets targeted at treating patients and supporting their caregivers.